Eli Lilly reported positive Phase 3 trial results for retatrutide, a triple hormone drug targeting obesity. Patients on the highest 12 mg dose lost an average of 28.3% of their body weight, with significant improvements in cardiovascular risk markers. The drug also helped many patients reduce their BMI below obesity thresholds. Further data from ongoing trials in diabetes and cardiovascular disease patients is expected later this year.
Eli Lilly reported a 55.5% revenue increase in Q1 2026, driven by strong sales of Mounjaro and Zepbound. Despite this growth and raised full-year guidance, shares have fallen due to pricing pressures from China and the U.S., and competition from Novo...
Eli Lilly's next-generation obesity drug, retatrutide, achieved significant weight loss in a late-stage trial, with patients losing up to 28.3% of their body weight over 80 weeks. The drug, which targets three gut hormones, outperformed existing trea...
Incyte has signed a $120 million partnership with Genesis Molecular AI, including $80 million upfront and a $40 million equity investment, to advance AI-driven drug discovery. This deal could exceed $1 billion with future milestones and royalties, us...
Eli Lilly has filed a civil lawsuit alleging a $200 million rebate fraud scheme involving several bishops of the Church of God in Christ and a Florida mail-order pharmacy, DrugPlace. The scheme involved false claims for rebates on the diabetes drug T...
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin...
